New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|November 19, 2013
The Developmental Process of MK-3475 in Melanoma
Author(s)Antoni Ribas, MD, PhD
Antoni Ribas, MD, PhD, discusses the development process of PD-1 antibody MK-3475 in melanoma.
Advertisement
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the development process of PD-1 antibody MK-3475 in melanoma.
Clinical Pearls
- MK-3475 has gone through phase I testing
- Physicians are eagerly awaiting data from a phase II clinical trial comparing chemotherapy to MK-3475 in patients who have previously received ipilimumab
- A trial studying two dosing regimens of MK-3475 compared to ipilimumab in frontline therapy for patients with metastatic melanoma is currently accruing
- MK-3475 is also being developed in other cancers, such as lung, bladder, and head and neck
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
4
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
5